← boardnext 2026-11-01next 2028-04
ERAS
Erasca, Inc.distress 4/10 · elevated risk$18.91-3%today-16% from 52w high
Oncology 4
Lead: RAS-mutant solid tumors · target ERK
Revenue
pre-revenue
Liquidity
$409M
Runway
4.5 yrs
Shares 1y
+10%
Price & events
+83.7% over 6M
CatalystRating changeDilutionFinancingdashed = today
-3.1%
1D
-0.6%
1W
+25.4%
1M
-15.9%
3M
+89.8%
6M
+1005.6%
1Y
+504.0%
2Y
-1.1%
5Y
+8.5%
All
Overview
- Market Cap
- $5.88B
- Volume
- 508.09K
- 52 Week Range
- $1.39 – $22.47
- Total Shares
- 310.98M
- Float Shares
- 247.63M
- Short %
- 11.66%
- % Held by Insiders
- 10.66%
- % Held by Institutions
- 93.59%
- RVOL
- 0.09x
- Beta
- 0.67
Pipeline stages · 2 programs
ERAS-4001, ERAS-4001 in combination
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Naporafenib, Dacarbazine, Temozolomide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 8 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-11-01 Estimated 50% readout ~2026-12-16 | Phase 1/2 | ERAS-007, ERAS-601 | Advanced or Metastatic Solid Tumors | — | active not recruiting |
| 2028-04 Estimated 50% readout ~2028-06-15 | Phase 3 | Naporafenib, Dacarbazine, Temozolomidefast track | Advanced or Metastatic NRAS-mutant Melanoma | — | active not recruiting |
| 2028-05-01 Estimated 50% readout ~2028-05-31 | Phase 1 | ERAS-0015, ERAS-0015 in combination | Metastatic Solid Tumors | — | recruiting |
| 2028-08 Estimated 50% readout ~2028-08-31 | Phase 1 | ERAS-4001, ERAS-4001 in combination | Metastatic Solid Tumors | — | recruiting |
| 2026-02-01 | Phase 1 | ERAS-601, Cetuximab, Pembrolizumab | Advanced or Metastatic Solid Tumors | 90 | active not recruiting |
Show all 8 trials · 3 more ▾
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-08-15 | Phase 1/2 | ERAS-007, Encorafenib, Cetuximab | Metastatic Colorectal Cancer, Metastatic Pancreatic Ductal Adenocarcinoma | 101 | completed |
| 2025-07-01 | Phase 1 | Naporafenib, Trametinibfast track | Advanced or Metastatic Solid Tumors | 86 | active not recruiting |
| 2025-03-01 | Phase 1/2 | ERAS-007, ERAS-601, Gilteritinib | Acute Myeloid Leukemia | 0 | withdrawn |
Catalyst news & presentations · 9
- 2027Guided 40%readoutPhase 1ERAS-0015 · Monotherapy expansion data and combination dose escalation dataSEC 8-K
- 2027Guided 40%trial initiationsecondaryPhase 1ERAS-4001 · Initiation of monotherapy expansion cohorts and combination dose escalation cohortsSEC 8-K
- first half of 2027Guided 55%readoutPhase 1ERAS-0015 · Monotherapy expansion data and combination dose escalation data from AURORAS-1 trial.SEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryPhase 1ERAS-0015 · Initiation of monotherapy expansion cohorts and combination dose escalation cohortsSEC 8-K
- second half of 2026Guided 55%readoutPhase 1ERAS-4001 · Initial Phase 1 monotherapy data in patients with KRAS-mutant solid tumorsSEC 8-K
- 2026-08-12earningsEarningsEarnings releaseyahoo
- first half of 2026readoutPhase 1ERAS-0015 · Initial Phase 1 monotherapy data in patients with RAS-mutant solid tumorsSEC 8-K
- 2025readoutPhase 3naporafenib · Readout of randomized dose optimization data from Stage 1 of SEACRAFT-2 Phase 3 trialSEC 8-K
- January 14, 2025conferencedata presentationsecondaryPresentation at J.P. Morgan Healthcare Conference.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $23 (+21% upside) · 10 analysts
- 2026-07-20Morgan StanleyEqual-Weight
- 2026-07-14B of A SecuritiesNeutral
- 2026-06-04B of A SecuritiesUnderperform → Neutral
- 2026-05-12MizuhoOutperform
- 2026-04-27StifelBuy
- 2026-03-18JP MorganOverweight
Competitors — ERK
- none identified
Recent news
- 2026-07-23Lost Money on Erasca, Inc. (ERAS)? Join Class Action Suit Seeking Recovery - Contact SueWallSt - PR Newswire
- 2026-07-23Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
- 2026-07-23Notice to Long-Term Shareholders of Erasca, Inc. (NASDAQ: - GlobeNewswire
- 2026-07-23ERAS Stockholders Have Opportunity to Lead Erasca, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - ACCESS Newswire
- 2026-07-22Erasca, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline - StreetInsider
- 2026-07-22ERAS Deadline Alert: Levi & Korsinsky Reminds Erasca, Inc. (ERAS) Investors of Securities Class Action Deadline on August 10, 2026 - Morningstar
- 2026-07-22ERASCA, INC. INVESTORS WITH LOSSES HAVE UNTIL AUGUST 10, - GlobeNewswire
- 2026-07-22Erasca, Inc. Notice of August 10, 2026 Application Deadline - GlobeNewswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.